Too Much or Too Little Empiric Treatment for Pseudomonas aeruginosa in Community-acquired Pneumonia?
Authors:
Open Access
- 1 September 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 18 (9) , 1456-1458
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patientsEuropean Respiratory Journal, 2018
- Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosaChest, 2016
- Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction ScoreAntimicrobial Agents and Chemotherapy, 2016
- Gram-stain-based antimicrobial selection reduces cost and overuse compared with Japanese guidelinesBMC Infectious Diseases, 2015
- Individualizing Risk of Multidrug-Resistant Pathogens in Community-Onset PneumoniaPLOS ONE, 2015
- Risk factors and antibiotic therapy in P. aeruginosa community‐acquired pneumoniaRespirology, 2015
- Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired PneumoniaAnnals of the American Thoracic Society, 2015
- Stratifying Risk Factors for Multidrug-Resistant Pathogens in Hospitalized Patients Coming From the Community With PneumoniaClinical Infectious Diseases, 2011
- Validation of a Clinical Score for Assessing the Risk of Resistant Pathogens in Patients With Pneumonia Presenting to the Emergency DepartmentClinical Infectious Diseases, 2011